Orphazyme after FDA meeting: New phase II/III trial won't be necessary

No new phase II/III study is required pertaining to a potential US approval of the lead cnadidate arimoclomol, which is meant to treat Niemann-Pick disease type C, Chief Financial Officer at Orphazyme Anders Vadsholt tells MedWatch.

Photo: Orphazyme / PR

It appears that Orphazyme will steer clear of the worst case scenario on the path toward US approval with its lead candidate arimoclomol, a treatment for the neurodegenerative disease, Niemann-Pick disease type C (NPC).

Chief Financial Officer at Orphazyme Anders Vadsholt tells Medwatch that the US Food and Drug Administration (FDA) has returned to the company with no additional requirement for a new and costly phase II/III trial before the drug's resubmission. This comes after a June meeting between the FDA and the Copenhagen-based biotech company regarding the FDA's rejection of arimoclomol this summer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs